Sironax Advances Enrollment in Phase 2 FORGE-LM Obesity Trial of NAMPT Activator SIR4156

October 13, 2026
Read More
October 5, 2026

Sironax Named to Fierce Biotech’s “Fierce 15” List of the Most Innovative and Promising Private Biotechs of 2026

Read More
September 16, 2026

Sironax Announces Option Exercise and Asset Purchase

Read More
September 16, 2026

Sironax Announces Option Exercise & Asset Purchase of its Brain Delivery Platform: Perspectives from Dr. Shefali Agarwal, President & CEO

Read More
May 11, 2026

Sironax’s SARM1 Inhibitor SIR2501 Granted FDA Fast Track Designation in Chemotherapy-induced Peripheral Neuropathy (CIPN)

Read More
April 22, 2026

Sironax Announces Abstract on SARM1 Inhibitor SIR2501 Selected for Presentation at 2026 ASCO Annual Meeting

Read More
March 26, 2026

Sironax Appoints Clive Wang to Board of Directors

Read More